Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05208190 · ClinicalTrials.gov registry record · Phase 4
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
A Phase 4 study of Schizophrenia and Schizoaffective Disorder, sponsored by New York State Psychiatric Institute.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 280
- Enrollment target
- 7
- Study locations
NCT05208190 is a Phase 4 study of Schizophrenia and Schizoaffective Disorder that is actively recruiting participants, run by New York State Psychiatric Institute. The registered enrollment target is 280 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (28% higher). The trial reports 7 study locations across 5 states.
The verdict
NCT05208190, a Phase 4 study of Schizophrenia and Schizoaffective Disorder, is actively recruiting participants, sponsored by New York State Psychiatric Institute.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 280 participants
- Enrollment target
- 7
- Study locations
Study Summary
Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU) for reducing the risk of violent acts in real-world settings
Conditions Studied
Interventions
- DRUG Clozapine
- DRUG treatment as usual
Study Locations (7)
New York
- NYU Langone Medical Center - New York
- New York State Psychiatric Institute - New York
- Manhattan Psychiatric Center - New York
California
- University of California, Los Angeles - Los Angeles
Georgia
- Augusta University Research Institute, Inc. - Augusta
Maryland
- University of Maryland School of Medicine - Baltimore
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2022-03-17 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05208190
The ClinicalTrials.gov registry entry for NCT05208190 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (28% higher). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Clozapine is the first listed.
NCT05208190 reports 7 study locations spanning 5 distinct geographic areas - top geographies include New York, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT05208190 about?
NCT05208190 is a clinical study titled "Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial". Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU) for reducing the r...
What is the current status of trial NCT05208190?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 280 participants. The study started on 2022-03-17. Estimated completion is 2028-12-31.
What conditions does trial NCT05208190 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT05208190?
The interventions under investigation include: Clozapine (DRUG), treatment as usual (DRUG).
Who is sponsoring clinical trial NCT05208190?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05208190 being conducted?
This trial has 7 study locations across California, Georgia, Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
-
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.